SCHEMBL1637345

SCHEMBL1637345

O=C(CC(=NNC(=O)c1sc2cc(F)ccc2c1Cl)C(F)(F)F)c1ccco1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.57
MAPT P10636 6/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
SENP1 Q9P0U3 1/20 0.53
TLR3 O15455 1/20 0.49
ALDH1A1 P00352 6/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 7/20 0.47
NPC1 O15118 3/20 0.47
TSHR P16473 1/20 0.47
BCKDK O14874 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
TP53 P04637 2/20 0.43
POLB P06746 1/20 0.42
OGG1 O15527 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637344 1.00 HPGD (0.57) HPGDMAPTSMN1; SMN2SENP1TLR3
SCHEMBL12726733 1.00 HPGD (0.57) HPGDMAPTSMN1; SMN2SENP1TLR3
SCHEMBL13971520 0.90 MAPT (0.51) HPGDMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL1639211 0.89 MAPT (0.57) HPGDMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL1639215 0.89 MAPT (0.57) HPGDMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL12726693 0.89 MAPT (0.57) HPGDMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL1638768 0.88 HPGD (0.58) HPGDMAPTSMN1; SMN2SENP1TLR3
SCHEMBL1638767 0.88 HPGD (0.58) HPGDMAPTSMN1; SMN2SENP1TLR3
SCHEMBL1638927 0.84 SENP1 (0.48) HPGDMAPTSMN1; SMN2SENP1TLR3
SCHEMBL1638925 0.84 SENP1 (0.48) HPGDMAPTSMN1; SMN2SENP1TLR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 HPGD 2613/4885MAPT 85/4885SMN1; SMN2 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.